Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)

Exclusion Criteria

• •Active suicidal ideation within the previous 3 months
• •On a tricyclic antidepressant, monoamine oxidase inhibitor, esketamine, or vortioxetine.
• •A history of clinically diagnosed dementia of any type
• •Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening
• •Has a BMI or body weight that will interfere with participation in the trial
• •Type I or Type II diabetes requiring insulin
• •Clinically significant ECG abnormalities
• •Participation in another clinical trial of a drug or device
• •Trial participants who in the opinion of the Investigator exhibit physical, cognitive, or language impairments of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
• •Positive testing for HIV, hepatitis B surface antigen, or hepatitis C antibodies at Screening.
• •Participants with a history of drug abuse or addiction in the past 2 years
• •Current use of cannabis/marijuana, or tetrahydrocannabinol-containing medications.